Jack A. Khattar – Supernus CEO and Myobloc
Jack A. Khattar is the founder, President, and Chief Executive Officer of Supernus Pharmaceuticals. His relevance to the botulinum toxin industry comes from Supernus’s current company role around Myobloc / Neurobloc and the company’s broader CNS commercialization context.
Khattar’s role helps separate current commercial company identity from product origin. Myobloc has an earlier Solstice Neurosciences and US WorldMeds history, while Supernus became the current U.S. company context through its 2020 agreement to acquire the US WorldMeds CNS portfolio.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Supernus Pharmaceuticals |
| Current role | Founder, President, and Chief Executive Officer |
| Industry relevance | Supernus leadership for Myobloc’s current company and CNS portfolio context |
| Relevant company | Supernus Pharmaceuticals |
| Relevant brand | Myobloc / Neurobloc |
| Market context | Neurology-focused commercial portfolio rather than aesthetic type A toxin commercialization |
Career Notes
Section titled “Career Notes”- Supernus identifies Khattar as founder, President, Chief Executive Officer, and Director.
- Supernus describes itself as a CNS-focused company with experience developing and commercializing products for neurological and psychiatric conditions.
- Supernus lists Myobloc among its commercial products.
- Supernus announced in 2020 that it would acquire US WorldMeds’ CNS portfolio, including Myobloc.
Myobloc Company Context
Section titled “Myobloc Company Context”Khattar matters because Myobloc’s current company context is easy to miss. The product is not a type A aesthetic competitor, and it is not best explained through Botox, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo comparison logic.
Supernus gives Myobloc a current U.S. commercial-company context, while the product remains rimabotulinumtoxinB, a botulinum toxin type B product with its own label, unit system, indications, and safety language.
Activity and Public Context
Section titled “Activity and Public Context”Khattar’s Supernus and Myobloc relevance is current company leadership behind the Myobloc portfolio. Product-specific claims should remain anchored to Myobloc prescribing information.